Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary

NCT05241132 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Cancer of Unknown Primary
Bone Cancer Metastatic
Tislelizumab
Gene Mutation-Related Cancer
Immune Evasion, Tumor
Chemotherapy Effect

Interventions

DRUG: Tislelizumab plus chemotherapy

Sponsor

Wei Xu